ReACT Therapeutics, a Grenoble-based biotech founded in January 2023, aims to restore cancer treatment efficacy and enhance remission rates in patients who have failed therapy. Our breakthrough drug class inhibits Breast Cancer Resistance Protein (BCRP), a transporter responsible for treatment resistance. With our lead drug, ValOMé, we extend the duration of drug effect and can impact 40 known cancer drugs across 14 indications.